CV Sciences (CVSI) Long-Term Investments (2013 - 2014)
CV Sciences (CVSI) reported Long-Term Investments of $400694.0 for Q1 2014, up 60.28% on a YoY basis from $250000.0 in Q1 2013, and down 8.78% sequentially from $439246.0 in Q4 2013.
CV Sciences (CVSI) Long-Term Investments (2013 - 2014) Analysis & Trends
CV Sciences (CVSI) has 2 years of Long-Term Investments data on file, last reported at $400694.0 in Q1 2014.
- For the quarter ending Q1 2014, Long-Term Investments rose 60.28% year-over-year to $400694.0; the trailing twelve-month figure through Mar 2014 stood at $400694.0 (up 60.28% YoY), and the FY2013 full-year result was $439246.0, changed N/A from the prior year.
- Long-Term Investments fell to $400694.0 in Q1 2014, from $439246.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $650000.0 in Q3 2013 to a low of $250000.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 400,694.00 |
| Dec 31, 2013 | 439,246.00 |
| Sep 30, 2013 | 650,000.00 |
| Jun 30, 2013 | 500,000.00 |
| Mar 31, 2013 | 250,000.00 |